brand logo

Am Fam Physician. 2001;63(5):848

to the editor: I was pleased to read the article1 on management of nonmalignant pain. The undertreatment of pain is a widespread issue in the United States, and helping to educate practicing family physicians in the most current pain management techniques is an important, even critical, goal.

I was disappointed, however, by the relative lack of information in the article on the two newest classes of oral analgesics: (1) tramadol (Ultram) and (2) cyclooxygenase-2 (COX-2) inhibitors, which represent a new type of non-steroidal anti-inflammatory drug (NSAID).

Tramadol has been available in the United States for five years. It is effective not only for an acute episode of neuropathic pain (as suggested in the article), but also for chronic neuropathic pain syndrome, fibromyalgia, osteoarthritis pain2 and chronic low back pain.3 Tramadol may be most notable for what it is not—tramadol is not an NSAID, nor is it a typical opioid. Tramadol has a dual mechanism of action: it acts centrally at μ-opioid receptors and acts spinally, inhibiting the reuptake of monoamines (serotonin and nor-epinephrine). This may explain why tramadol and antidepressants are effective for some analgesic-resistant pain states.4

COX-2 inhibitors (rofecoxib [Vioxx] and celecoxib [Celebrex]) are used for a variety of indications: acute pain, dysmenorrhea and osteoarthritis. Further research is needed on the use of these drugs in the treatment of other painful states, but it is reasonable to assume, based on the available evidence, that COX-2 inhibitors are generally as effective as nonselective NSAIDs. Therefore, in cases of acute low back pain or chronic nonmalignant pain, COX-2 inhibitors should be especially useful for patients with inflammation and who are at high risk for gastrointestinal bleeding. Patients with such risk factors include those receiving treatment with “dual” NSAIDs, those receiving concomitant gluco-corticoid treatment, those with a history of gastroduodenal ulcers or bleeding and those receiving anticoagulation therapy.5,6

The use of COX-2 inhibitors may be appropriate in chronic and acute pain states; however, they may still be associated with non-gastrointestinal adverse events (e.g., renal, hepatic, cardiovascular).5,6

It is critically important that family physicians continue to be familiar with all aspects of pain management. I commend your efforts to call attention to the importance of this subject in primary care.

editor's note: A copy of this letter was sent to the author of “Treatment of Nonmalignant Chronic Pain,” who declined to reply.

Email letter submissions to afplet@aafp.org. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors. Letters submitted for publication in AFP must not be submitted to any other publication. Letters may be edited to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

Continue Reading


More in AFP

More in PubMed

Copyright © 2001 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.